EDWARDS LIFESCIENCES CORPORATION |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 88.74 USD | -0.85% |
|
-4.54% | +17.04% |
| 01:07pm | Truist Raises Price Target on Edwards Lifesciences to $110 From $105, Maintains Buy Rating | MT |
| 07-15 | Sector Update: Health Care Stocks Edge Lower Late Afternoon | MT |
Edwards Lifesciences Corporation specializes in designing, manufacturing and marketing medical systems and devices for treating cardiovascular diseases. Net sales break down by family of products as follows:
- heart valves and surgery products (67.9%);
- hemodynamic monitoring systems (15.5%);
- other (16.6%): balloon catheters, artificial implants, etc.
Net sales are distributed geographically as follows: the United States (58.4%), Europe (22.2%), Japan (7.6%) and other (11.8%).
Calendar
24/07/2024
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
89.5
USD
Average target price
96.28
USD
Spread / Average Target
+7.57%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +17.04% | 53.93B | |
| +3.38% | 208B | |
| +6.94% | 182B | |
| +30.07% | 155B | |
| +34.73% | 115B | |
| +2.55% | 66.52B | |
| -4.51% | 46.26B | |
| -4.84% | 38.22B | |
| +4.16% | 36.6B | |
| +19.75% | 30.16B |
- Stock Market
- Equities
- EW Stock
- News Edwards Lifesciences Corporation
- Truist Raises Price Target on Edwards Lifesciences to $110 From $105, Maintains Buy Rating
